Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DMAC | US
0.04
0.61%
Healthcare
Biotechnology
30/06/2024
16/04/2026
6.62
6.55
6.64
6.35
DiaMedica Therapeutics Inc. a clinical stage biopharmaceutical company develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199 a recombinant human tissue kallikrein-1 protein which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis Minnesota.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
49.4%1 month
52.6%3 months
55.1%6 months
63.1%-
-
3.43
0.01
0.01
-0.96
-
-
-22.35M
282.99M
282.99M
-
-
-
-
-35.18
2.37
0.52
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.17
Range1M
1.76
Range3M
3.33
Rel. volume
0.55
Price X volume
837.36K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| NextCure Inc | NXTC | Biotechnology | 11 | 307.73M | -12.63% | n/a | 7.21% |
| AC Immune SA | ACIU | Biotechnology | 3.07 | 303.75M | -2.23% | n/a | 0.00% |
| LRMR | LRMR | Biotechnology | 4.72 | 301.17M | -2.28% | n/a | 2.65% |
| Enanta Pharmaceuticals Inc | ENTA | Biotechnology | 14.06 | 297.91M | -3.37% | n/a | 151.88% |
| Inventiva S.A | IVA | Biotechnology | 5.63 | 296.98M | -1.92% | n/a | -115.26% |
| CEL-SCI Corporation | CVM | Biotechnology | 4.64 | 295.97M | 5.94% | n/a | 143.19% |
| Moolec Science SA Ordinary Shares | MLEC | Biotechnology | 7.85 | 294.07M | 3.15% | n/a | 209.19% |
| Anavex Life Sciences Corp | AVXL | Biotechnology | 3.4 | 288.30M | 4.94% | n/a | 0.00% |
| Aclaris Therapeutics Inc | ACRS | Biotechnology | 3.98 | 283.95M | 1.27% | n/a | 2.10% |
| Akebia Therapeutics Inc | AKBA | Biotechnology | 1.35 | 283.89M | -12.90% | n/a | -309.96% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.24 | 310.38M | 1.25% | n/a | 174.23% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.63 | 264.90M | 0.39% | 13.23 | 0.00% |
| Urban One Inc | UONEK | Broadcasting - Radio | 4.87 | 258.15M | 0.00% | n/a | 268.43% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 17.89 | 199.61M | 1.02% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.74 | 156.39M | 0.72% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.99 | 100.48M | 0.63% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.12 | 99.69M | 0.49% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.93 | 74.70M | 1.14% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.32 | 59.96M | 0.00% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 14 | 21.32M | 2.04% | n/a | 204.46% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.96 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.43 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 55.09 | 72.80 | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 282.99M | 3.66B | Emerging |